Keywords: Teva, XM02, Neutropenia, Biosimilars, Amgen, Neupogen

Teva files BLA for XM02 with FDA for chemotherapy-induced neutropenia; a challenge to Amgen’s Neupogen?

Article | 02 December 2009

Print This

Israel’s Teva Pharmaceutical Industries, better known as a global leader in the generic drug sector, has submitted a Biologics ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in